Gilead Rises on Hepatitis C Trial Results: San Francisco Mover
This article is for subscribers only.
Gilead Sciences Inc., the drugmaker that acquired Pharmasset Inc. last month for its experimental hepatitis C treatments, gained the most in three years after one of the medicines produced positive clinical trial results.
Gilead rose 11 percent to $54.70 at the close of trading in New York, its biggest single-day gain since Oct. 13, 2008. The shares of the Foster City, California-based drugmaker have increased 41 percent in the last 12 months.